Skip to content
  • Career
  • Support
  • Contact Us
Menu
  • Career
  • Support
  • Contact Us
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
Menu
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
Search
Close
Menu
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get a Quote
    • Get Set Up
  • News & Events
    • News
    • Events
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
  • Career
  • Support
  • Contact Us
  • All posts

AMRA Medical and Fulcrum Therapeutics Develop MRI Method for Multi-site Neuromuscular Clinical Trials

  • April 2, 2020

Visualization of the degree of fat affected muscles in an FSHD study from healthy muscle (green) to severely fat replaced (red)

LINKÖPING, Sweden; April 2, 2020 – In collaboration, AMRA Medical and Fulcrum Therapeutics created a standardized whole-body magnetic resonance imaging (MRI) protocol to evaluate skeletal muscle composition in patients with facioscapulohumeral dystrophy (FSHD) – a slowly progressing muscular dystrophy. An abstract describing this work was accepted and made publicly available by the Muscular Dystrophy Association.

Clinical trial investigators commonly use functional tests such as the 6-Minute Walk Test and single-slice MRI to evaluate neuromuscular disease progression. These techniques can vary substantially, creating unwanted data noise – potentially making trials larger, longer and more costly. Additionally, there is a lack of standards for implementing whole-body MRI in multi-center trials, making it challenging to quantify how the disease affects individual muscles throughout the body in different stages of the disease. Lastly, neuromuscular disease studies often emphasize only the legs.  This study includes whole muscle volumes in the legs, trunk, shoulders, and arms.

AMRA and Fulcrum conducted a study to evaluate, optimize and standardize a whole-body MRI protocol for use in clinical trials for Fulcrum’s losmapimod – a small molecule investigational therapeutic for FSHD. Together, they successfully developed a detailed musculoskeletal MRI protocol to quantify muscle fat fraction, lean muscle volume, and muscle fat infiltration. They volumetrically and bilaterally analyzed 18 individual muscles in 16 adults with FSHD across 6 clinical sites using diverse MRI scanner manufacturers. Fulcrum recognizes that AMRA’s technology is a significant advancement in neuromuscular clinical trials and plans to use this protocol as part of the further development of losmapimod.

Diego Cadavid, Fulcrum Therapeutics’ Senior Vice President of Clinical Development says “Commonly used endpoints – such as functional tests – have limitations, so we engaged with AMRA based on their ability to reliably and quickly segment and quantify muscles. Together we developed an MRI protocol that generates stable images from which AMRA’s algorithms produce consistent, quality, objective and reproducible biomarkers that we now use in our ongoing clinical trial program.”

This study further demonstrates that AMRA’s MRI technology:  1) has the potential to follow heterogeneous disease distribution; 2) is compatible with major MRI scanner manufacturers, making multicenter trials more feasible; 3) can perform whole-body 3D volumetric measurements of individual muscles and muscle groups, enabling earlier and more accurate detection of fat and muscle changes; and 4) can longitudinally monitor several different muscles specific to the neuromuscular disorder and patient.

These results rationalize the exploration and use of AMRA’s methods in additional neuromuscular clinical trials. The full abstract for Development and Evaluation of a Whole-Body MRI Imaging Protocol And Analysis Algorithms to Measure Changes in Skeletal Muscle in FSHD (#142) can be viewed on the MDA 2020 website.

Learn more about AMRA Medical’s technology, research, and opportunities for collaboration by visiting www.amramedical.com.

  • All posts
Follow us
Linkedin Twitter Facebook

About

AMRA offers clinical services and research services to support transformative care and vital decision-making, from clinical research to clinical care.

Contact

  • info@amramedical.com
  • +46 (0) 13 16 26 00
  • Contact Our Support
  • Data Privacy Policy
  • Cookie Policy
  • Data Privacy Policy
  • Cookie Policy

Newsletter

    © 2023 AMRA Medical AB

    AMRA Medical
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    View preferences
    {title} {title} {title}
    AMRA Medical
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    View preferences
    {title} {title} {title}